Skip to main content

Table 1 Demographics of subjects at baseline

From: Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease

Characteristics CN (n = 52) sMCI (n = 22) pMCI (n = 47) AD (n = 18)
Age (years) 76.2 (5.1) 76.0 (5.1) 73.1 (6.6) 74.3 (7.0)
Gender, female (%) 22 (42.3%) 7 (31.8%)d 14 (29.8%)d 11 (61.1%)
Education (years) 15.7 (3.3) 16.8 (2.4) 15.9 (2.7) 15.2 (2.9)
APOE ε4, n (%) 10 (19.2%)c,d 7 (31.8%)c,d 28 (59.6%)a,b 13 (72.2%)a,b
MMSE 29.3 (1.0)b,c,d 27.2 (1.4)a,d 26.6 (1.6)a,d 24.2 (2.1)a,b,c
ADAS-cog 5.9 (2.8)b,c,d 9.2 (3.8)a,c,d 12.5 (4.3)a,b,d 18.2 (6.1)a,b,c
Aβ42 (pg/ml) 211.4 (56.2)b,c,d 181.0 (54.7)a,c,d 147.5 (47.8)a,b 136.1 (27.3)a,b
t-tau (pg/ml) 72.7 (28.5)c,d 84.7 (54.0)d 107.8 (49.3)a,d 153.2 (78.7)a,b,c
t-tau/Aβ42 0.399 (0.283)c,d 0.553 (0.492)c,d 0.820 (0.501)a,b,d 1.138 (0.569)a,b,c
p-tau (pg/ml) 24.6 (10.4)c,d 28.1 (15.7)c,d 39.5 (16.5)a,b 45.8 (16.4)a,b
p-tau/Aβ42 0.135 (0.095)c,d 0.184 (0.147) c,d 0.303 (0.162)a,b 0.350 (0.145)a,b
Follow-up (years) 7.5 (2.6)b,c,d 4.8 (2.5)a,d 5.7 (2.6)a,d 2.6 (0.7)a,b,c
  1. Values are shown as mean ± standard deviation unless otherwise indicated
  2. p values indicate the values assessed with analyses of variance for each variable except gender and APOE ε4, where a contingency chi-square was performed. Post-hoc analysis provided significant differences between groups: a versus CN; b versus sMCI; c versus pMCI; d versus AD.
  3. amyloid-β, AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale cognitive subscale, APOE apolipoprotein E, CN cognitively normal, MMSE Mini-Mental State Examination, pMCI progressive mild cognitive impairment, p-tau phosphorylated tau, sMCI stable mild cognitive impairment, t-tau total tau